OTLK Outlook Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why OTLK matters now
Outlook Therapeutics, Inc. (OTLK) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.57 with -6.55% on the session and $64.6M in market capitalization; recent performance reads 1-month +591.77% and YTD +0.00%.
The latest financial table shown here is Q2 2026, with revenue of $127.4K, net income of $-4.5M, and EPS of $-0.17. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -72.4%.
The latest indexable market news headline is "OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $1.00; recent insider activity includes Haddadin Yezan Munther filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-4.46
P/S
195.12
EV/EBITDA
-1.36
DCF Value
$0.38
FCF Yield
-72.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
-360.9%
Operating Margin
-18182.8%
Net Margin
-18297.5%
ROE
178.1%
ROA
-278.4%
ROIC
5446.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $127.4K | $-4.5M | $-0.17 |
| Q1 2026 | $-1.2M | $-23.1M | $-0.38 |
| Q4 2025 | $-91.8K | $-13.3M | $-0.52 |
| FY 2025 | $1.4M | $-62.4M | $-1.79 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$1.00
Target (Median)
$1.00
Target Range
$1.00 - $1.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.98
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.